Boston Scientific Gets Positive Results for Heart-Failure Device
26 10월 2023 - 4:32AM
Dow Jones News
By Sabela Ojea
Boston Scientific said its clinical trial to treat coronary
in-stent restenosis with its investigational device met its primary
endpoint, reducing the risk of heart failure.
The biotechnology company said the positive outcomes from its
Agent Drug-Coated Balloon support the device as an alternative
treatment option for coronary in-stent restenosis.
"We look forward to using these encouraging data to support FDA
approval and bringing this important therapy to more physicians and
patients in need," said Janarthanan Sathananthan, chief medical
officer at interventional cardiology therapies.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
October 25, 2023 15:17 ET (19:17 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Boston Scientific (NYSE:BSX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Boston Scientific (NYSE:BSX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
